Actively Recruiting

Age: 18Years +
All Genders
NCT07361289

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Led by Bristol-Myers Squibb · Updated on 2026-05-11

500

Participants Needed

15

Research Sites

136 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to assess the effectiveness of mavacamten treatment in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in real-world clinical practice

CONDITIONS

Official Title

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants aged 18 years or older at the time of initial mavacamten prescription
  • Participants who have started or are scheduled to start mavacamten based on clinical need
  • Diagnosed with obstructive hypertrophic cardiomyopathy according to current American and European guidelines
  • Documented left ventricular outflow tract gradient of 30 mmHg or higher at rest or with provocation within 3 months prior to enrollment
  • Left ventricular ejection fraction of 55% or higher measured by resting transthoracic echocardiography within 3 months prior to enrollment
  • New York Heart Association (NYHA) class II or III symptoms documented within 3 months prior to enrollment
  • For retrospective participants, essential baseline information and critical data must be available, with at least one key follow-up time point recorded
  • Provided voluntary informed consent
Not Eligible

You will not qualify if you...

  • Known hypertrophic cardiomyopathy phenocopy diseases such as Fabry disease or amyloidosis
  • Expected to undergo major cardiac surgery during the study
  • Received invasive septal reduction treatment within 6 months prior to enrollment, including surgical myectomy or alcohol septal ablation
  • Currently treated with disopyramide or ranolazine within 14 days prior to enrollment or expected to take these or certain other medications during the study
  • Presence of other diseases that may prevent completion of 96 weeks follow-up
  • Using or expected to use moderate to strong CYP2C19 or CYP3A4 inhibitors or inducers during the study
  • Participating in other interventional clinical studies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

Local Institution - 0008

Beijing, Beijing Municipality, China, 100029

Not Yet Recruiting

2

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100032

Actively Recruiting

3

Peking University First Affiliated Hospital

Beijing, Beijing Municipality, China, 100034

Actively Recruiting

4

Local Institution - 0009

Guangzhou, Guangdong, China, 510080

Not Yet Recruiting

5

The Second Afilliated Hospital of Hebei Medical University

Jiazhuang, Hebei, China, 050000

Actively Recruiting

6

Local Institution - 0003

Harbin, Heilongjiang, China, 150086

Not Yet Recruiting

7

Local Institution - 0007

Zhengzhou, Henan, China, 450052

Not Yet Recruiting

8

Suzhou Municipal Hospital

Suzhou, Jiangsu, China, 215002

Actively Recruiting

9

The Second Hospital of Jilin University

Changchun, Jilin, China, 130041

Actively Recruiting

10

Local Institution - 0005

Dalian, Liaoning, China, 116011

Not Yet Recruiting

11

Local Institution - 0013

Xi'an, Shan3xi, China, 710061

Not Yet Recruiting

12

West China Hospital of Sichuan University

Chengdu, Sichuan, China, 610041

Actively Recruiting

13

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310009

Actively Recruiting

14

Local Institution - 0010

Jinan, China, 250012

Not Yet Recruiting

15

Zhongshan Hospital Fudan University

Shanghai, China, 200032

Actively Recruiting

Loading map...

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

F

First line of the email MUST contain NCT # and Site #.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China | DecenTrialz